Urologists attending localized prostate cancer sessions at the upcoming AUA annual meeting in Washington will hear more about the ongoing debate on open versus minimally invasive radical prostatectomy, the use of 5-alpha-reductase inhibitors (5-ARIs) in men on active surveillance, and updates on treatment approaches such as high-intensity focused ultrasound.
In the case of prostatectomy techniques, researchers arrived at conflicting findings, said Dr. Gomella, professor and chairman of urology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia. One large review including more than 110,000 patients found a lower complication rate among patients undergoing robotic RP compared with the open technique, as well as overall lower perioperative morbidity and improved early oncologic outcomes.
"This is based on a literature review and not on actual discharge records, leading to a potential publication bias toward more favorable outcome reporting," Dr. Gomella said of the study.
A Brazilian prospective trial pronounced robot-assisted laparoscopic RP a safe technique, with lower blood loss and more favorable International Index of Erectile Function scores than seen with the open (retropubic) approach.
"This is a unique prospective trial that will yield important data," Dr. Gomella predicted. "It is unlikely that a similar prospective randomized clinical trial could be completed in the U.S. due to the strong patient preference for robotically assisted radical prostatectomy."
EV/pembrolizumab under review in China for advanced urothelial carcinoma
March 28th 2024The sBLA is supported by findings from the phase 3 EV-302 trial, which showed that EV/pembrolizumab extended overall survival and progression-free survival vs platinum-based chemotherapy in patients with advanced urothelial carcinoma.
Potential code for prior authorizations on AMA CPT Editorial Panel meeting agenda
March 28th 2024"Good public and economic policy must align costs, benefits, and incentives; currently, all costs are incurred by physician practices, and all financial savings and benefits from prior authorization accrue to health insurance plans, leading to perverse incentives,” says Alex Shteynshlyuger, MD.